Authors' Reply to Letter to the Editor.

作者：Choi Hyon; Neogi Tuhina; Stamp Lisa; Dalbeth Nicola; Terkeltaub Robert

来源：Arthritis & Rheumatology, 2018.

DOI：10.1002/art.40742

We appreciate Dr. Kuwabara's sharing FEATHER study data in relation to our article(2) about the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial. As pointed out, we agree that the FEATHER study's overall cardiovascular (CV) disease outcome results(4) tended to be consistent with the CARES trial findings, although its sample size was >10 time smaller than the CARES trial and underpowered for that purpose. The author states no difference of CV mortality, but no data are provided, although the number of CV deaths would be less than the overall CV event rates (4/219 in febuxostat and 7/222 in placebo).(4) To that end, these data appear to add minimally to the causal inference about the CV impact of febuxostat.

• 单位
  Boston university; x